$GLUEMonte Rosa Therapeutics, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down
  Adecto Pharmaceuticals’ 12-year story has come to an end as the immunotherapy biotech blamed a “risk-averse funding environment” for shutting up shop.
  fiercebiotech · 8h ago
• Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
  Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
  biospace · 3d ago
• Enveda, an AI drugmaker, banks $311M in venture funding
  Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.
  biopharma_dive · 8d ago
• Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
  Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
  biopharma_dive · 1mo ago
• Research into protein interactions sheds new light on causes of autism
  Studying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists at the University of California, San Francisco has suggested.
  fiercebiotech · 1mo ago
• With $263M, LifeMine unearths a new drug for organ transplants
  Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
  biopharma_dive · 1mo ago
• Novo’s late-stage IL-6 stumble shakes inflammation space
  Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s…
  biospace · 2mo ago
• Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
  The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.
  biopharma_dive · 2mo ago
• STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end
  After July 1, Medicare will offer GLP-1 weight-loss drugs for $50. It's supposed to be temporary, but chances are it won't be.
  stat · 3mo ago
• Covid vaccination cut risk of adverse heart events, large study finds
  Covid vaccination was also tied to a nearly 24% reduction in all-cause cardiac events in a large study, surprising researchers.
  stat · 3mo ago